NVP Healthcare
Total Healthcare company who is responsible for human health from care to Cure.
2025
▪Obtained individual recognition of functional ingredient for NVP-2106 from MFDS
▪Completed US FDA Pre-IND meeting for LC4146 new drug
2024
▪Obtained a marketing approval of NVP-2002
in Korea
▪Completed US FDA Pre-IND meeting
for LC2767 new drug
2023
▪Launched Bicrome Liver-Care Probiotics
(NVP-1702) in Korea
▪Obtained individual recognition of functional
ingredient for NVP-1702 from MFDS
▪Obtained a marketing approval of NVP-1102
in Russia
2022
▪Obtained a marketing approval of NVP-1203
in Korea
▪Initiated human study of functional probiotics
for NVP-2201
▪Initiated human study of functional probiotics
for NVP-2106
▪Launched Bicrome Stress-Care Probiotics
(NVP-1704) in Korea
▪Changed the company name to NVP Healthcare
Co. Ltd
▪Opened Seoul Office
2021
▪Obtained a marketing approval of
NVP-1901 in Korea
2020
▪Launched Bicrome Nose-Care Probiotics
(NVP-1703) in Korea
▪Signed a license-out agreement of
NVP-1102 in Russia
2019
▪Approved IND for clinical trial phase III of NVP-1203
▪Launched NVP-1503 in Korea
▪Obtained individual recognition of functional ingredient
for NVP-1703 from MFDS
▪Initiated human study of functional
probioticsfor NVP-1905
2018
▪Initiated human study of functional
probiotics for NVP-1704
▪Obtained Exclusive Marketing Approval
of NVP-1504 from MFDS
2017
▪Designated as ¡°Pharmaceutical Testing
Laboratory¡± by MFDS
▪Initiated human study of functional
probiotics for NVP-1702
▪Initiated human study of functional
probiotics for NVP-1703
2016
▪Relocated headquarters and Research Institute to
new company building
▪Obtained a marketing approval of NVP-1205
in Korea
2015
▪Signed a license-out agreement of NVP-0902
in Mexico
▪Obtained a marketing approval of NVP-1102
in Korea
2013
▪Signed a license-out agreement of NVP-0902
with Roche
▪Obtained a marketing approval
of NVP-0902 in Korea
2012
▪Signed a license-out agreement of NVP-1102
2011
▪Signed a license-out agreement of NVP-0902
2010
▪Signed an agreement with Thomson
Reuters on providing and updating NCE
& DMF Information in Korea
▪Registered as Venture Business
Company and Company Affiliated
Research Institute
2009
▪Moved into ¡°Gyeonggi Small and
Medium Business Supporting Center¡±
and established Research Institute
2008
▪Constructed and managed MFDS¡¯s
Patent Informatics DB from August 2008
to December 2013
▪Founded Navipharm Co., Ltd.
Copyright© NVP Healthcare Co., LTD.
All rights reserved.
TEL031-895-5438
E-MAIL info@nvp-healthcare.com
